- Home
- OPRX vs AUTL Comparison
OPRX vs AUTL Comparison
Compare OPRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRX
- AUTL
- Stock Information
- Founded
- OPRX 2006
- AUTL 2014
- Country
- OPRX United States
- AUTL United Kingdom
- Employees
- OPRX N/A
- AUTL N/A
- Industry
- OPRX Business Services
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPRX Consumer Discretionary
- AUTL Health Care
- Exchange
- OPRX Nasdaq
- AUTL Nasdaq
- Market Cap
- OPRX 380.6M
- AUTL 415.2M
- IPO Year
- OPRX N/A
- AUTL 2018
- Fundamental
- Price
- OPRX $18.25
- AUTL $1.75
- Analyst Decision
- OPRX Buy
- AUTL Strong Buy
- Analyst Count
- OPRX 8
- AUTL 5
- Target Price
- OPRX $11.81
- AUTL $9.12
- AVG Volume (30 Days)
- OPRX 373.4K
- AUTL 4.6M
- Earning Date
- OPRX 11-12-2025
- AUTL 11-11-2025
- Dividend Yield
- OPRX N/A
- AUTL N/A
- EPS Growth
- OPRX N/A
- AUTL N/A
- EPS
- OPRX N/A
- AUTL N/A
- Revenue
- OPRX $104,748,000.00
- AUTL $29,934,000.00
- Revenue This Year
- OPRX $17.92
- AUTL $641.63
- Revenue Next Year
- OPRX $10.91
- AUTL $109.21
- P/E Ratio
- OPRX N/A
- AUTL N/A
- Revenue Growth
- OPRX 25.89
- AUTL 185.17
- 52 Week Low
- OPRX $3.78
- AUTL $1.11
- 52 Week High
- OPRX $20.70
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- OPRX 49.17
- AUTL 48.20
- Support Level
- OPRX $17.45
- AUTL $1.45
- Resistance Level
- OPRX $18.93
- AUTL $1.65
- Average True Range (ATR)
- OPRX 1.14
- AUTL 0.10
- MACD
- OPRX -0.24
- AUTL 0.03
- Stochastic Oscillator
- OPRX 21.08
- AUTL 56.09
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.